TY - JOUR
T1 - Primary care visit use after positive fecal immunochemical test for colorectal cancer screening
AU - Hillyer, Grace Clarke
AU - Jensen, Christopher D.
AU - Zhao, Wei K.
AU - Neugut, Alfred I.
AU - Lebwohl, Benjamin
AU - Tiro, Jasmin A.
AU - Kushi, Lawrence H.
AU - Corley, Douglas A.
N1 - Funding Information:
Supported by National Cancer Institute grants 3U54CA163262-04S1 (Principal Investigator: Douglas A. Corley) and U24CA171524 (Principal Investigator: Lawrence H. Kushi).
Publisher Copyright:
© 2017 American Cancer Society
PY - 2017/10/1
Y1 - 2017/10/1
N2 - BACKGROUND: For some patients, positive cancer screening test results can be a stressful experience that can affect future screening compliance and increase the use of health care services unrelated to medically indicated follow-up. METHODS: Among 483,216 individuals aged 50 to 75 years who completed a fecal immunochemical test to screen for colorectal cancer at a large integrated health care setting between 2007 and 2011, the authors evaluated whether a positive test was associated with a net change in outpatient primary care visit use within the year after screening. Multivariable regression models were used to evaluate the relationship between test result group and net changes in primary care visits after fecal immunochemical testing. RESULTS: In the year after the fecal immunochemical test, use increased by 0.60 clinic visits for patients with true-positive results. The absolute change in visits was largest (3.00) among individuals with positive test results who were diagnosed with colorectal cancer, but significant small increases also were found for patients treated with polypectomy and who had no neoplasia (0.36) and those with a normal examination and no polypectomy performed (0.17). Groups of patients who demonstrated an increase in net visit use compared with the true-negative group included patients with true-positive results (odds ratio [OR], 1.60; 95% confidence interval [95% CI], 1.54-1.66), and positive groups with a colorectal cancer diagnosis (OR, 7.19; 95% CI, 6.12-8.44), polypectomy/no neoplasia (OR, 1.37; 95% CI, 1.27-1.48), and normal examination/no polypectomy (OR, 1.24; 95% CI, 1.18-1.30). CONCLUSIONS: Given the large size of outreach programs, these small changes can cumulatively generate thousands of excess visits and have a substantial impact on total health care use. Therefore, these changes should be included in colorectal cancer screening cost models and their causes investigated further. Cancer 2017;123:3744–3753.
AB - BACKGROUND: For some patients, positive cancer screening test results can be a stressful experience that can affect future screening compliance and increase the use of health care services unrelated to medically indicated follow-up. METHODS: Among 483,216 individuals aged 50 to 75 years who completed a fecal immunochemical test to screen for colorectal cancer at a large integrated health care setting between 2007 and 2011, the authors evaluated whether a positive test was associated with a net change in outpatient primary care visit use within the year after screening. Multivariable regression models were used to evaluate the relationship between test result group and net changes in primary care visits after fecal immunochemical testing. RESULTS: In the year after the fecal immunochemical test, use increased by 0.60 clinic visits for patients with true-positive results. The absolute change in visits was largest (3.00) among individuals with positive test results who were diagnosed with colorectal cancer, but significant small increases also were found for patients treated with polypectomy and who had no neoplasia (0.36) and those with a normal examination and no polypectomy performed (0.17). Groups of patients who demonstrated an increase in net visit use compared with the true-negative group included patients with true-positive results (odds ratio [OR], 1.60; 95% confidence interval [95% CI], 1.54-1.66), and positive groups with a colorectal cancer diagnosis (OR, 7.19; 95% CI, 6.12-8.44), polypectomy/no neoplasia (OR, 1.37; 95% CI, 1.27-1.48), and normal examination/no polypectomy (OR, 1.24; 95% CI, 1.18-1.30). CONCLUSIONS: Given the large size of outreach programs, these small changes can cumulatively generate thousands of excess visits and have a substantial impact on total health care use. Therefore, these changes should be included in colorectal cancer screening cost models and their causes investigated further. Cancer 2017;123:3744–3753.
KW - colorectal cancer
KW - delivery of health care
KW - early detection of cancer
KW - primary health care
UR - http://www.scopus.com/inward/record.url?scp=85021406005&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021406005&partnerID=8YFLogxK
U2 - 10.1002/cncr.30809
DO - 10.1002/cncr.30809
M3 - Article
C2 - 28621809
AN - SCOPUS:85021406005
SN - 0008-543X
VL - 123
SP - 3744
EP - 3753
JO - Cancer
JF - Cancer
IS - 19
ER -